ReviewCancer chemotherapy and pharmacology2026

First-in-class HIF-2α therapy in genitourinary oncology: Belzutifan from von Hippel-Lindau disease to advanced renal cell carcinoma.

Irem Karaman et al.PubMed ↗Publisher ↗

No numbers read from the abstract.